F-8-IL-12 fusion protein (Philogen)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameF-8-IL-12 fusion protein (Philogen)

Drug Alias NameDodecalF-8-IL-2-TNF mut fusion proteinF-8-IL-12

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionInterleukin-2 receptor agonistsInterleukin-12 receptor stimulantsIntegrin beta-1 modulators

TargetsIntegrin beta-1Interleukin-12 receptorInterleukin-2 receptor

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPhilogen Spa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPhilogen Spa

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A